Motustx Security Rating

Motus is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases. Our lead product candidate, relamorelin, is a potent, best-in-class, Phase 2 ghrelin agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders. We believe this product candidate has the potential to treat gastrointestinal conditions for which there are currently limited therapeutic options. We believe that ghrelin is a compelling target because of its critical role in regulating GI function and metabolism, and that peptide therapeutics are well suited for activating this target. We have completed two Phase 2 clinical trials of relamorelin for the treatment of diabetic gastroparesis and chronic constipation, and additional Phase 2 clinical trials are under way in diabetic gastroparesis and lower GI functional disorders. The FDA has granted Fast Track designation to relamorelin for the treatment of diabetic gastroparesis.